Tawen Chang
9 IP cases indexed. Covers patent matters.
Cases Presided Over
9 cases indexed | Page 1 of 1
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned the PTAB to institute an IPR against Merus N.V.'s patent (9358286) concerning heterodimeric Ig-like molecules. The Board found sufficient evidence of unpatentability under 35 U.S.C. §§ 102 and 103, advancing the dispute into the substantive review phase.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to institute IPR against Seikagaku Corporation's patent (11236318) based on grounds of lack of written description and obviousness. The Board found sufficient evidence at this preliminary stage, allowing the challenge to proceed into full litigation.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories successfully secured the institution of its IPR against California Institute of Technology's patent, challenging claims based on anticipation and obviousness. The Board found that Bio-Rad demonstrated a reasonable likelihood of prevailing regarding Claim 1 over Larson.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
The PTAB issued a Final Written Decision rejecting all claims (1-19) of the '921 patent. The Board rejected arguments based on obviousness and novelty, particularly concerning multi-occupancy droplet detection in multiplexed biochemical assays.
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
The petitioner failed to prove the obviousness of claims 1-20 of U.S. Patent No. 7883848 in a Final Written Decision. The Board adopted a specific claim construction for 'selecting all cis-reactive cells exhibiting the detectable trace,' defining it as selecting associations of at least two interactor moieties joined by an associated oligonucleotide that exhibit the detectable trace.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
The PTAB denied Bio-Rad Laboratories' request for rehearing regarding the denial of institution in IPR2024-01178, upholding its finding that the petitioner failed to meet the burden of proving unpatentability.
Encube Ethicals Pvt. Ltd. v.Dermavant Sciences GmbH et al.
Encube Ethicals successfully challenged Dermavant Sciences' patent claims in the PTAB, leading to institution of the case. The Board found sufficient grounds for anticipation (102) and obviousness (103), specifically regarding psoriasis treatment methods. This decision significantly strengthens Encube's position by validating their prior art arguments against the '088 patent.
Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.
Bruker Spatial Biology successfully petitioned the PTAB to institute an IPR against 10x Genomics, Inc., challenging numerous claims of patent 11542554. The Board found a reasonable likelihood that the challenged claims are unpatentable based on grounds of obviousness (35 U.S.C. § 103).
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.